With Theralis®, its fully automated system,
Theradiag is strengthening its positioning
in the diagnosis of auto-immune diseases

 

Croissy-Beaubourg, 27 March 2014 – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in-vitro diagnostics and theranostics, unveiled Theralis®, its new automated solution for auto-immune diseases diagnostics, at the International Auto-immunity Congress in Nice, France, gathering the international experts in these pathologies. Thanks to this comprehensive automated solution, Theradiag is strengthening its franchise in auto-immune diseases, a therapeutic segment in which the Company has more than twenty years of experience.

Theralis® is the new CE Marked fully automated system resulting from Theradiag’s research, providing one of the market’s most comprehensive multiplex set of assays. Steered by the new Solinium® multi-platform software, this new tool incorporates multiplex FIDIS®, immunofluorescence and ELISA technologies. All of a laboratory’s auto-immune analyses can thus be carried out using the same instrument. This new solution is unique on its market.

Polyvalent, Theralis® enables up to 120 samples and 60 tests to be loaded and 3 analysis methodologies to be carried out simultaneously. Theralis® thus meets the demands of public and private laboratories, which need greater polyvalence and speed to cope with their requirements, but also enhanced precision and reliability for patient diagnostics. This new platform further consolidates the multiple Fidis portfolio.

Theradiag enjoys substantial recognition in the auto-immunity sector. It is our core business within which we must continually innovate and excel in order to maintain our leadership position. With Theralis®, we are providing a state-of-the-art technical offer in multiplex technology, which is this market’s most efficient technology. This fully automated system supplements our in-house product offer, which covers all auto-immune diseases from screening via the FIDIS® range to the monitoring of biotherapies thanks to the Lisa-Tracker theranostic range”, says Michel Finance, CEO of Theradiag.

For more information about Theralis®, please go to:

http://www.theradiag.com/en/diagnostics/instrumentation/theralis/

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of HIV/AIDS and rectal cancer. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 60 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

Theradiag

Relations investisseurs

Nathalie Trepo

Tél: 01 64 62 10 12

ntrepo@theradiag.com

 

 NewCap.

Communication financière
et Relations Investisseurs

Valentine Brouchot /

Pierre Laurent

Tél. : 01 44 71 94 94

theradiag@newcap.fr

 

Alize RP

Relations Presse

Caroline Carmagnol

theradiag@alizerp.com

Tél. : 06 64 18 99 59